Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTG201 in Localized Prostate Cancer
NCT01931046Phase 2Completed
- Sponsor
- Momotaro-Gene Inc.
- Start
- Oct 2013
- Primary completion
- Jul 2018
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of MTG201 in prostate cancer (PCa), sponsored by Momotaro-Gene Inc.. Started Oct 2013; status: completed.
02
Drugs
MTG201
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01931046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01931046.